Paul Watt - Phylogica Insider

PYC -- Australia Stock  

AUD 0.025  0.003  10.71%

Chief Scientific Officer

Dr. Paul Michael Watt is NonExecutive Director of Phylogica Ltd. He is a graduate from The University of Western Australia. He completed his doctorate in Molecular Biology at Oxford University before taking up postdoctoral appointments in yeast genetics at Harvard and Oxford Universities. He discovered three novel genes, including the yeast homologue of the human Bloom and Werner syndrome genes involved in cancer susceptibility. He is an Honorary Research fellow at the Telethon Institute for Child Health Research and an Adjunct Professor at the school of Paediatrics and Child Health of the University for Western Australia. Dr. Watt has published more than 45 peer reviewed scientific papers. Dr. Watt has more than 12 years experience in commercializing intellectual property and is the primary inventor on 20 patents. He founded InfaMed Ltd., now owned by Avita Medical Ltd.
Age: 47  Executive Since 2016      
61 8 9489 7777  http://www.phylogica.com.au

Management Efficiency

The company has return on total asset (ROA) of (85.88) % which means that it has lost $85.88 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (91.1) % meaning that it generated substantial loss on money invested by shareholders.

Similar Executives

Showing few of many executives

EXECUTIVE Since

Angela MurphyChallenger Limited
2012
Bruce RosengartenCaltex Australia Limited
2014
Mike RoanMeridian Energy Limited
2017
Anna CurzonXero Limited
2017
Matthew RoweAustralian Foundation Investmen
2016
Paul RoganChallenger Limited
2011
Dean FradgleyFletcher Building Limited
2015
Charles BoltFletcher Building Limited
2013
Peter LimCaltex Australia Limited
2015
L InterligiCIMIC Group Limited
2010
Andrew LarkXero Limited
2014
Neal BarclayMeridian Energy Limited
2017
A HowseCIMIC Group Limited
2003
Philip KingFletcher Building Limited
N/A
Robert WoodsChallenger Limited
2015
Simon PordageAustralian Foundation Investmen
N/A
Craig HudsonXero Limited
2017
Richard HowesChallenger Limited
2017
Jason SteinMeridian Energy Limited
2010
Dean WerderSpark New Zealand Limited
2016
Ed McManusMeridian Energy Limited
2016

Entity Summary

Phylogica Limited provides drug discovery research and development services utilizing Phylomer peptide libraries and proprietary screening capabilities in Australia. It has approximately 12 patent families comprising multiple grantedallowed patents in the United States and Australia, which cover methods of making the Phylomer libraries methods of screening them and composition-of-matter claims for Phylomer libraries and individual Phylomer peptides discovered for therapeutic and diagnostic applications. Phylogica operates under Biotechnology classification in Australia and traded on Australian Securities Exchange.Phylogica Limited (PYC) is traded on Australian Securities Exchange in Australia. It is located in Telethon Kids Institute and employs 5 people.

Phylogica Limited Leadership Team

Douglas Wilson, Chairman, Ph.D
Bernard Hockings, Director, Ph.D
Paul Watt, Executive
Sahm Nasseri, Director, MBA
Kevin Hart, CFO
Graeme Boden, CFO, CPA
Rudi Michelson, Executive
Alan Tribe, Executive
Rick Kendall, Director, Ph.D
Stephanie Unwin, Director
Robert Hayes, Director, Ph.D
Bruce McHarrie, Director
Natasha Forde, Executive
Richard Hopkins, CEO
Michael Williams, Director
Jeremy CurnockCook, Director
Rohan Hockings, Director

Stock Performance Indicators

Current Sentiment - PYC

Phylogica Limited Investor Sentiment
Most of Macroaxis users are at this time bullish on Phylogica Limited. What is your perspective on investing in Phylogica Limited? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Trending Equities

Currently Active Assets on Macroaxis
OZL   
Purchased over 100 shares of
over a week ago
Traded for 10.44
FBU   
Purchased over 300 shares of
over a week ago
Traded for 6.24
JBH   
Purchased over 70 shares of
over a week ago
Traded for 23.42
GNC   
Purchased over 200 shares of
over a week ago
Traded for 8.1
SBM   
Purchased over 400 shares of
over a week ago
Traded for 4.74
Additionally take a look at Your Equity Center. Please also try Companies Directory module to evaluate performance of over 100,000 stocks, funds, and etfs against different fundamentals.